BioNTech SE

NASDAQ:BNTX

Biotechnology

Healthcare
$83.26 -1.52%

-$1.41 today

Market cap
$20.64B
Beta
1.32
P/E (TTM)
-16.2
EPS (TTM)
-$4.93
52W Low $79.52High $124.00

Volume 1.24M

Average 1.11M

BNTX Pre-Tax Margin

Income before tax as a percentage of revenue.

BioNTech SENASDAQ: BNTX

Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026

Pre-tax margin narrows to -813.2%

Pre-tax margin was -813.2% in Q2 FY2026, down 658.8 pp from a year earlier. On a trailing-twelve-month basis it was -61.9%, down 48.4 pp year over year. Over 3 fiscal years it narrowed by 111.4 pp.

Context

  • Pre-tax margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-813.2%-332.1 pp QoQ
Last fiscal yearDec 2025
-36.6%-12.0 pp YoY
LTMJun 2026
-61.9%-48.4 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-658.8 pp——
1 year-12.0 pp——
3 years-111.4 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-36.6%
Year-over-year change
-12.0pp

Pre-Tax Margin vs competitors

How BNTX compares with its peers on the latest reported figures

  • BNTX's LTM Jun 2026 pre-tax margin of -61.9% is the 8th highest of the 11 companies compared; the peer median is -23.6%.
  • Its year-over-year change of -48.4 pp is the 8th highest of 10, against a peer median of +0.2 pp.
  • Over three fiscal years its change of -111.4 pp compares with a peer median of +18.7 pp.
BNTX Competitors Peer median
Pre-Tax Margin for BNTX and competitors
Company Period LTM level YoY 3-year change
CGENCompugen Ltd.LTM Mar 202648.0% +82.8 pp+497.1 pp
INCYIncyte CorporationLTM Jun 202633.8% +6.3 pp+16.8 pp
GMABGenmab A/SLTM Jun 202621.9% —-15.5 pp
TGTXTG Therapeutics, Inc.LTM Sep 202616.7% +0.2 pp+8053.8 pp
IMCRImmunocore Holdings plcLTM Mar 2026-2.0% +4.8 pp+18.7 pp
MGNXMacroGenics, Inc.LTM Mar 2026-45.2% -9.2 pp+29.5 pp
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-58.5% +100.5 pp—
BNTXBioNTech SELTM Jun 2026-61.9% -48.4 pp-111.4 pp
XNCRXencor, Inc.LTM Jun 2026-153.2% -43.9 pp-38.1 pp
IMTXImmatics N.V.LTM Mar 2026-577.4% -565.0 pp-435.5 pp
IBRXImmunityBio, Inc.LTM Sep 2026-607.9% -185.5 pp+173558.8 pp
Peer median (excluding BNTX) -23.6%+0.2 pp+18.7 pp

Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.98B17.31B3.82B2.75B2.76B
Cost of Revenue2.91B3B599.8M541.3M616.47M
Gross Profit16.07B14.32B3.22B2.21B2.14B
Gross Margin84.7%82.7%84.3%80.3%77.6%
Research & Development949.2M1.54B1.78B2.25B2.02B
Selling, General & Admin327.2M541.2M557.7M599M698.2M
Operating Expenses781.4M1.67B2.53B3.52B2.76B
Depreciation & Amortization75.2M123.3M183.4M298M367.69M
EBITDA15B13.1B1.38B(367.1M)(628M)
EBITDA Margin79.1%75.7%36.1%-13.3%-22.8%
Operating Income15.28B12.64B690.4M(1.31B)(623.87M)
Operating Margin80.5%73.0%18.1%-47.8%-22.6%
Interest Income1.56M47.37M351.31M0252.24M
Interest Expense5.63M15.82M7.76M13.16M13.64M
Other Income / Expenses(237.4M)311.4M495.7M636.6M(385.46M)
Income Before Tax15.05B12.95B1.19B(677.7M)(1.01B)
Pre-Tax Margin79.3%74.8%31.1%-24.6%-36.6%
Income Tax Expense4.75B3.52B255.8M(12.4M)81.93M
Net Income10.29B9.43B930.3M(665.3M)(1.09B)
Net Margin54.2%54.5%24.4%-24.2%-39.6%
EPS (Basic)43.8738.083.87(2.77)(4.51)
EPS (Diluted)41.2137.093.83(2.77)(4.51)
Weighted Avg Shares244M243.3M240.6M240.4M241.7M
Weighted Avg Shares (Diluted)259.7M249.8M242.7M240.4M241.7M

BioNTech SE

NASDAQ:BNTX

Intrinsic Alpha fair value

Locked

Current Price

$83.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.